Needham Maintains Buy on G1 Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on G1 Therapeutics (NASDAQ:GTHX) but lowers the price target from $14 to $12.

February 13, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham maintains a Buy rating on G1 Therapeutics but lowers the price target from $14 to $12.
The reduction in price target by Needham, while maintaining a Buy rating, suggests a positive outlook on G1 Therapeutics but with adjusted expectations. This could lead to mixed reactions in the short term, as investors weigh the positive endorsement against the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100